Drug Type Biosimilar, Monoclonal antibody |
Synonyms Infliximab Biosimilar (Aprogen, Inc.), 英夫利西单抗生物类似药(Aprogen, Inc.), AP-07 |
Target |
Action inhibitors |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |

| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Autoimmune Diseases | Preclinical | South Korea | 01 Jan 2022 |






